Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update

Fundamental and Clinical Pharmacology

Volumn 19, Issue 1, 2005, Pages 117-125

  Schachter, Michael ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Efficacy; Hypercholesterolaemia; Pharmacokinetics; Safety; Statins

Indexed keywords

ATORVASTATIN; CARRIER PROTEIN; CERIVASTATIN; CHOLESTEROL; CYTOCHROME P450; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; TRIACYLGLYCEROL;

ACTIVE TRANSPORT; CARDIOVASCULAR RISK; CELL MEMBRANE; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; DYSLIPIDEMIA; FIRST PASS EFFECT; HUMAN; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; LIPOPHILICITY; LIVER CELL; LIVER METABOLISM; MUSCLE DISEASE; MUSCLE TOXICITY; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEINURIA; RARE DISEASE; REVIEW; RHABDOMYOLYSIS; STATISTICAL SIGNIFICANCE;

CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA;

EID: 13444251203     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2004.00299.x     Document Type: Review

References (72)

1. De Backer G., Ambrosioni E., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur. Heart J. (2003) 24 1601-1610.
2. National Cholesterol Education Program (NCEP). Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol (Adult Treatment Panel III). JAMA (2001) 285 2486-2497.
3. Hobbs H.H., Brown M.S., Goldstein J.L. Molecular genetics of the LDL receptor gene in familial hypercholesterolaemia. Hum. Mutat. (1992) 1 445-466.
4. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation (2000) 101 207-213.
5. Ginsberg H.N., Le N.A., Short M.P., Ramakrishnan R., Desnick R.J. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin: implications for the regulation of apolipoprotein B synthesis. J. Clin. Invest. (1987) 80 1692-1697.
6. Grundy S.M. Consensus statement: role of therapy with 'statins' in patients with hypertriglyceridemia. Am. J. Cardiol. (1998) 81 (Suppl. 4A) 1B-6B.
7. Liao J.K. Beyond lipid lowering: the role of statins in vascular protection. Int. J. Cardiol. (2002) 86 5-18.
8. Christians U., Jacobsen W., Floren L.C. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol. Ther. (1998) 80 1-34.
9. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. (1999) 84 413-428.
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344 1383-1389.
11. Shepherd J., Cobbe S.M., Ford I. et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333 1301-1307.
12. Sacks P.M., Pfeffer M.A., Moye L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. (1996) 335 1001-1009.
13. Downs J.R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279 1615-1622.
14. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. (1998) 339 1349-1357.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 360 7-22.
16. Shepherd J., Blauw G.J., Murphy M.B. et al. on behalf of the PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 360 1623-1630.
17. Sever P.S., Dahlöf B., Poulter N.R. et al., for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361 1149-1158.
18. Vaughan C.J., Gotto A.M., Jr, Basson C.T. The evolving role of statins in the management of atherosclerosis. J. Am. Coll. Cardiol. (1999) 35 1-10.
19. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J., Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet (2001) 357 577-581.
20. Furberg C.D., Pitt B. Withdrawal of cerivastatin from the world market. Curr. Control Trials Cardiovasc. Med. (2001) 2 205-207.
21. Davidson M.H. Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin. Invest. Drugs (2002) 11 125-141.
22. Gaw A., Packard C.J. Comparative chemistry, pharmacology and mechanism of action of the statins, in: Gaw A., Packard C.J., Shepherd J. (Eds), Statins. The HMG CoA reductase inhibitors in perspective, Martin Dunitz, London, 2000, pp. 49-61.
23. McTavish D., Sorkin E.M. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs (1991) 42 65-89.
24. McTaggart F., Buckett L., Davidson R., et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol. (2001) 87 (Suppl. B) 28-32.
25. Istvan E.S., Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science (2001) 292 1160-1164.
26. Corsini A., Maggi F.M., Catapano A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res. (1995) 31 9-27.
27. Kajinami K., Mabuchi H., Saito Y. NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin. Investig. Drugs (2000) 9 2653-2661.
28. Cilia D.D. Jr, Gibson D.M., Whitfield L.R., Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J. Clin. Pharmacol. (1996) 36 604-609.
29. Tse F.L., Jaffe J.M., Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J. Clin. Pharmacol. (1992) 32 630-638.
30. Pan H.Y., DeVault A.R., Wang-Iverson D., Ivashkiv E., Swanson B.N., Sugerman A.A. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J. Clin. Pharmacol. (1990) 30 1128-1135.
31. Warwick M.J., Dane A.L., Raza A., Schneck D.W. Single and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522. Atherosclerosis (2000) 151 39.
32. Martin P.D., Mitchell P.D., Schneck D.W. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br. J. Clin. Pharmacol. (2002) 54 472-477.
33. Singhvi S.M., Pan H.Y., Morrison R.A., Willard D.A. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. (1990) 29 239-243.
34. Naoumova R.P., Dunn S., Rallidis L. et al. Prolonged inhibition of cholesterol synthesis explains the eflicacy of atorvastatin. J. Lipid Res. (1997) 38 1496-1500.
35. Yang B-B., Smithers J.A., Stern R.H. et al. Pharmacokinetics and dose proportionality of atorvastatin and its active metabolites. Pharm. Res. (1996) 13 (Suppl. 1) S437.
36. Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. (2003) 42 1141-1160.
37. Martin P.D., Warwick M.J., Dane A.L., Brindley C., Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin. Ther. (2003) 25 2553-2563.
38. Muck W., Ritter W., Ochmann K. et al. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int. J. Clin. Pharmacol. Ther. (1997) 35 255-260.
39. Garnett W.R. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am. J. Health Syst. Pharm. (1995) 52 1639-1645.
40. Radulovic L.L., Cilia D.D., Posvar E.L., Sedman A.J., Whitfleld L.R. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. J. Clin. Pharmacol. (1995) 35 990-994.
41. Smith H.T., Jokubaitis L.A., Troendle A.J., Hwang D.S., Robinson W.T. Pharmacokinetics of fluvastatin and specific drug interactions. Am. J. Hypertens. (1993) 6 375S-382S.
42. Pan H.Y., DeVault A.R., Brescia D. et al. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int. J. Clin. Pharmacol. Ther. Toxicol. (1993) 31 291-294.
43. Hamelin B.A., Turgeoun J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. TiPS (1998) 19 36-37.
44. Nezasa K., Higaki K., Takeuchi M., Nakano M., Koike M. Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica (2003) 33 379-388.
45. Rosenson R.S., Tangney C.C. Antiatherosclerolic properties of statins: implications for cardiovascular event reduction. JAMA (1998) 279 1643-1650.
46. Bottorff M., Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism - monograph for physicians. Arch. Intern, Med. (2000) 160 2273-2280.
47. Michalets E.L. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy (1998) 18 84-112.
48. Jacobsen W., Kuhn B., Soldner A. et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos. (2000) 28 1369-1378.
49. Vickers S., Duncan C.A., Vyas K.P. et al. In vitro and in vivo biotransformation of simvastatin. an inhibitor of HMG CoA reductase. Drug Metab. Dispos. (1990) 18 476-483.
50. Lennernäs H., Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Clin. Pharmacokinet. (1997) 32 403-425.
51. Fujino H., Yamada I., Kojima J., Hirano M., Matsumoto H., Yoneda M. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (5): in vitro metabolism and plasma protein binding in animals and human. Xeno. Metab. Disp. (1999) 14 415-424.
52. McCormick A.D., McKillop D., Butters C.J. et al. ZD4522 - an HMG-CoA reductase inhibitor free of metabolically mediated drug interactions: metabolic studies in human in vitro systems. J. Clin. Pharmacol. (2000) 40 1055.
53. Schachter M. Statins, drug interactions and cytochrome P450. Br. J. Cardiol. (2001) 8 311-317.
54. Sica D.A., Gehr T.W. Rhabdomyolysis and statin therapy: Relevance to the elderly. Am. J. Geriatr. Cardiol. (2002) 11 48-55.
55. Muscari A., Puddu G.M., Puddu P. Lipid-lowering drugs: Are adverse effects predictable and reversible? Cardiology (2002) 97 115-121.
56. Knopp R.H. Drug treatment of lipid disorders. N. Engl. J. Med. (1999) 341 498-511.
57. Quion J.A.V., Jones P.H. Clinical pharmacokinetics of pravastatin. Clin. Pharmacokinet. (1994) 27 94-103.
58. Martin P.D., Warwick M.J., Dane A.L. et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin. Ther. (2003) 25 2822-2835.
59. Simonson S.G., Martin P.D., Mitchell P., Schneck D.W., Lasseter K.C., Warwick M.J. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur. J. Clin. Pharmacol. (2003) 58 669-675.
60. Olsson A.G., Pears J., McKellar J., Mizan J., Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am. J. Cardiol. (2001) 88 504-508.
61. Jones P., Kafonek S., Laurora I., Hunninghake D. for the CURVIËS Investigators. Comparative dose efficacy of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolaemia. Am. J. Cardiol. (1998) 81 582-587.
62. Jones P.H., Davidson M.H., Stein E.A. et al. for the STELLAR Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am. J. Cardiol. (2003) 92 152-160.
63. Saito Y., Yamada N., Teramoto T. et al. A randomized double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesteremia. Atherosclerosis (2002) 162 373-379.
64. Black D.M. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr. Atheroscler. Rep. (2002) 4 34-41.
65. Staffa J.A., Chang J., Green J. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. (2002) 346 539-540.
66. Ballantyne C.M., Corsini A., Davidson M.H. et al. Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. (2003) 163 553-564.
67. Thompson P.D., Clarkson P., Karas R.H. Statin-associated myopathy. JAMA (2003) 289 1681-1689.
68. Newman C.B., Palmer G., Silbershatz H., Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am. J. Cardiol. (2003) 92 670-676.
69. Brewer H.B. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. (2003) 92 (Suppl.) 23K-29K.
70. Rosenson R.S. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev. Cardiovasc. Ther. (2003) 1 495-505.
71. Sidaway J., Davidson R., McTaggart F. et al. Effect of statins on protein uptake and cholesterol biosynthesis in kidney proximal tubule cells (abstract). Toxicol. Lett. (2003) 144 (Suppl. 1) S96.
72. Verhulst A., D'Haese P.C., De Broe M.E. Statins inhibit endocytosis in the proximal tubule. J. Am. Soc. Nephrol. (2002) 14 376A.